Key result
Remnant cholesterol reduction fails to reduce cardiovascular events, unlike LDL-C and non-HDL-C lowering.
Why the study?
Does remnant cholesterol reduction reduce cardiovascular events in adults?
Meta-Analysis
Does remnant cholesterol reduction reduce cardiovascular events in adults?
Answers are grounded in this paper and cite their sources.
In a meta-regression of 43 large clinical trials, lowering remnant cholesterol did not reduce cardiovascular events, suggesting it may not be a useful independent therapeutic target.
BACKGROUND: Despite extensive efforts to lower low-density lipoprotein cholesterol (LDL-C), cardiovascular disease remains highly prevalent. Remnant cholesterol (RC) has been proposed as a potentially more relevant therapeutic target. OBJECTIVE: To evaluate the association between RC reduction and cardiovascular outcomes in randomized controlled trials (RCTs) of cholesterol- and triglyceride-lowering therapies, assessing whether RC independently influences cardiovascular risk. METHODS: Cochrane Central and Embase were searched for RCTs with ≥1000 participants and ≥2 years' planned duration that assessed cholesterol- or triglyceride-lowering therapies vs placebo, usual care, or other lipid-lowering drugs in adults. Two reviewers independently extracted data and evaluated methodological quality. Meta-analysis and meta-regression were performed. RESULTS: Forty-three RCTs met the inclusion criteria; most had some risk of bias, and evidence certainty was moderate. Meta-analysis showed absolute risk reductions of 0.4% (95% CI 0.1%-0.6%) for all-cause mortality, 1.3% (95% CI 1.1%-1.6%) for myocardial infarction, and 0.4% (95% CI 0.2%-0.6%) for stroke in treatment vs control groups. Meta-regression demonstrated no association between RC reduction and any clinical outcome, whereas LDL-C and non-high-density lipoprotein cholesterol reductions were associated with risk reduction. CONCLUSION: RC reduction was not associated with cardiovascular benefit. This contrasts with observational and Mendelian randomization studies, likely reflecting methodological differences; MR estimates lifelong genetically mediated exposure and may not reliably predict the effects of short-term pharmacological lipid lowering. LAY SUMMARY: In a review of 43 large clinical trials, lowering "remnant cholesterol" did not reduce heart attacks, strokes, or deaths - unlike lowering LDL ("bad") cholesterol, which did - suggesting that remnant cholesterol may not be a useful treatment target despite earlier studies hinting otherwise.Summary sentence A review of 43 clinical trials found that lowering remnant cholesterol did not translate into fewer deaths, heart attacks, or strokes.
No takes yet. Share an insight, caveat, or question.
Byrne et al. (2026) conducted a meta-analysis in Cardiovascular disease. Cholesterol- or triglyceride-lowering therapies vs. Placebo, usual care, or other lipid-lowering drugs was evaluated on All-cause mortality (ARR 0.4%, 95% CI 0.1-0.6). In a meta-regression of 43 RCTs, remnant cholesterol reduction was not associated with any clinical cardiovascular outcome, whereas LDL-C and non-HDL-C reductions were associated with risk reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: